Sequent Scientific Limited has informed the Exchange regarding Proceedings of Court Convened General Meeting held on August 30, 2025 along with a copy of minutes.
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sequent Scientific Limited held a meeting of its equity shareholders on August 30, 2025, as directed by the NCLT Hyderabad Bench, to consider a Composite Scheme of Amalgamation. The scheme involves the merger of Sequent Scientific with Symed Labs Limited, Vandana Life Sciences, Appcure Labs, Vindhya Pharma, S.V. Labs, Vindhya Organics, Viyash Life Sciences, Geninn Life Sciences, and Sequent Research Limited, along with their respective shareholders and creditors. The Managing Director and CEO briefed shareholders on the rationale, share exchange ratios, and benefits of the proposed scheme. Shareholders approved the resolution with the requisite majority — three-fourths in value, majority in number, and majority of public shareholders — as required under the Companies Act, 2013 and SEBI's master circular on schemes of arrangement. Voting results and the scrutinizer's report have already been submitted to the stock exchanges.
This is a significant step forward in a large-scale consolidation in the life sciences space. Shareholder approval clears a key milestone, but the scheme still requires further NCLT and regulatory approvals before it can become effective, so the deal is not yet closed.